Page 24 - கீல்வாதம் மருத்துவ நோயெதிர்ப்பு ஆராய்ச்சி ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

On April 10, 2020, MedPage Today
published a story on the success seen with guselkumab (Tremfya) for psoriatic arthritis in two large pivotal phase III trials, DISCOVER-1 and DISCOVER-2. Guselkumab is a monoclonal antibody that binds the interleukin-23 p19 subunit, and was approved for use in psoriasis in July 2017.
On July 14, 2020 the FDA approved guselkumab for psoriatic arthritis, based on the results of the DISCOVER trials.
In DISCOVER-1, which included 381 patients with active psoriatic arthritis who were either biologic-naive or had previously been treated with a tumor necrosis factor inhibitor, a 20% improvement on the response criteria of the American College of Rheumatology (ACR20) was observed at week 24 in 59% of patients given 100 mg of guselkumab subcutaneously every 4 weeks and by 52% of those receiving the medication every 8 weeks compared with 22% of those randomized to receive placebo. ....

Health Assessment Questionnaire , American College Of Rheumatology , Medpage Today , American College , Psoriasis Area , Severity Index , Short Form , Health Assessment Questionnaire Disability , Aggressive Behavior , Psoriasis With Arthropathy , அமெரிக்கன் கல்லூரி ஆஃப் வாத நோய் , அமெரிக்கன் கல்லூரி , தடிப்புத் தோல் அழற்சி பரப்பளவு , தீவிரம் குறியீட்டு , குறுகிய வடிவம் ,